Swedish Professor Backs Rejection of Alzheimer's Drug Leqembi: 'No Proven Benefit'

The decision by Swedish authorities not to approve the Alzheimer's drug Leqembi reflects a cautious and evidence-based approach to medical treatment, a stance that aligns with the rigorous standards upheld by the Swedish healthcare system. Svenska Dagbladet reports on this development, highlighting the perspective of Ole Isacson, a professor of neurology and neuroscience, who contends that the drug lacks proven efficacy.

Professor Isacson's viewpoint, as presented in the article, is crucial. He argues that Leqembi, which involves anti-amyloid antibody infusions, has not shown a demonstrable benefit that would justify its widespread use in Sweden. This position underscores the national priority placed on ensuring that treatments are not only innovative but also demonstrably effective and safe before being integrated into patient care. The fact that Sweden has withheld approval, unlike some other nations, speaks to its commitment to patient welfare and the responsible allocation of healthcare resources.

“

It is good that Sweden has not approved treatment with the drug Leqembi for patients with Alzheimer's disease.

While the article notes that some patients have sought this treatment abroad, driven by hope for improvement, this situation also brings into focus the differing regulatory landscapes and treatment accessibility across countries. From a Swedish perspective, however, the focus remains on validated medical science. Svenska Dagbladet frames this as a responsible decision, prioritizing patient outcomes based on robust scientific evidence over the potential, yet unproven, benefits of a new therapy. The national discourse emphasizes the importance of rigorous clinical validation, a principle deeply embedded in Swedish medical ethics.

“

Several interviews described in detail how patients, with hope for improvement, have traveled abroad because they could not receive this potential treatment in Sweden.